BSE Pharma Sector Regulatory Filings — April 16, 2026

Successfully paid interest on three NCD series (INE634S07017: ₹498cr gross, INE634S07025: ₹498cr, INE634S07033: ₹994cr) on due date April 16, 2026, net of taxes with no delays

Fully redeemed 1,25,000 NCDs of INE634S07017 series for ₹1,250 crore on April 16, 2026, reducing outstanding debt to ₹0 for this series vs prior balance

On-time debt servicing (interest record date April 1, 2026; last payment Oct 16, 2025) outperforms sector peers with neutral filings, highest materiality 6/10

Board to consider final dividend recommendation for FY 2025-26 under Reg 29 SEBI LODR, signaling potential capital return vs no such activity in other filings

Dividend intimation follows March 23, 2026 notice, consistent process across NSE/BSE/NYSE, neutral sentiment but positive for yield-focused investors

Q4FY26 audited results and earnings call scheduled May 13, 2026 at 1600 IST with leadership Q&A, multi-timezone dial-ins provided for broad access

Earnings transcript to be posted on www.cipla.com post-call, enabling detailed analysis vs peers without such transparency commitments

Debt redemption materiality (6/10) exceeds Cipla (4/10) and Dr. Reddy's (3/10), positive sentiment outlier in neutral sector

Dividend focus complements earnings catalyst, dual capital allocation signals stronger than single-event peers

2/3 filings highlight returns/debt reduction (dividend consideration + NCD redemption), no buybacks/splits but prudent vs reinvestment

Q4FY26 results on May 13, 2026 could reveal unreported period-over-period declines if trends weaken, neutral sentiment masks potential volatility

Board 'will consider' FY25-26 final dividend 'if any', prior March 23 intimation but no guaranteed payout vs historical norms

Fully redeemed one series (INE634S07017) but two others (07025/07033) still outstanding post-interest payment, future servicing needs monitoring

Multiple dial-in options (Universal +91 22 6280 1562 etc.) but toll-free limited to USA/UK/HK/SG, potential low participation if technical issues

Intimation under Reg 29 to multiple exchanges (NSE/BSE/NYSE), any delays in board decision could flag governance concerns

2/3 filings neutral (Cipla/Dr. Reddy's), lacks bullish financial trends or insider buys, potential for downside if earnings disappoint

Last interest Oct 16, 2025 timely, but any future delays on remaining series could reverse positive debt signal

Post-₹1,250cr NCD redemption (outstanding now ₹0), potential re-rating for lower leverage vs peers with ongoing debt, positive sentiment

Board consideration for FY25-26 final dividend offers yield alpha if approved, multi-exchange listing enhances liquidity

Q4FY26 call May 13, 2026 with leadership Q&A and transcript, position ahead for guidance/upside surprises in pharma growth

Timely ~₹1,989cr gross interest across series + full redemption signals strong cash flows, undervalued if debt discount persists

Comprehensive dial-ins (toll-free USA/UK/HK/SG) + IR contact for pre-call queries, edge for active investors vs passive

Reg 29 compliance and Hyderabad HQ stability, pair with sector rotation into dividend plays amid neutral peers

Cluster of catalysts (earnings + dividend + debt milestone) in 1-day period, short-term trading alpha from volatility

Higher materiality (6/10 vs 4/10) on debt success, relative outperformance play ahead of Cipla earnings

Mankind's full NCD redemption (₹1,250cr) and timely interest (~₹1,989cr gross) highlight pharma deleveraging trend, positive for balance sheets vs no peer debt updates [IMPLICATION: Lower risk profiles attract FII inflows]

Dr. Reddy's dividend consideration + Mankind redemption show shift to shareholder returns/debt paydown (2/3 filings), no M&A/buybacks [IMPLICATION: Yield enhancement in stable sector]

Cipla earnings May 13 + Dr. Reddy's board dividend decision, event-driven volatility in neutral sentiment environment [IMPLICATION: Trade around dates for alpha]

2/3 neutral (Cipla/Dr. Reddy's) vs 1 positive, no YoY/QoQ declines reported but lacks growth signals [IMPLICATION: Cautious positioning pre-events]

All filings to BSE/NSE (+NYSE/Lux), timely intimations (Reg 29 for Dr. Reddy's), governance strength across constituents [IMPLICATION: Reduced regulatory overhang]

Mankind leads at 6/10 (debt), Cipla 4/10 (earnings), Dr. Reddy's 3/10 (dividend), outliers signal relative conviction [IMPLICATION: Allocate to high-materiality names]

Results release + conference call May 13, 2026 at 1600 IST, watch for YoY/QoQ trends, guidance, margins in pharma update

Post-May 13 on www.cipla.com, monitor for forward-looking statements and leadership commentary

Consider FY25-26 final dividend per Reg 29, follow-up from March 23 intimation, watch announcement timeline

Series INE634S07025/07033 interest paid April 16, next due ~Oct 2026 (per Oct 2025 pattern), track future redemptions

Post-INE634S07017 full redemption, monitor impact on D/E ratio and credit ratings

Cross-listed RDY, watch US investor reaction to dividend intimation

Investor.Relations@cipla.com for pre-earnings queries, dial-in tests ahead of May 13

No current trades reported, watch for patterns post-events across BSE PHARMA constituents